RT Journal Article
T1 Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
A1 López-Díaz, Álvaro
A1 Murillo-Izquierdo, Manuel
A1 Moreno-Mellado, Elisa
K1 Treatment-resistant depression
K1 antidepressants
K1 ketamine
AB Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone.
YR 2019
FD 2019-04-29
LK http://hdl.handle.net/10668/13886
UL http://hdl.handle.net/10668/13886
LA en
DS RISalud
RD Apr 10, 2025